Empagliflozin (JARDIANCE®) is proven to go beyond lowering A1C to reduce the risk of CV death for adults who have type 2 diabetes and heart disease
Prof. Melanie Davies - T2D Guidelines Recommendation
05/02/2025 | Author: Boehringer Ingelheim
Document ID: PC-PH-106209